Biogen, Eisai’s lecanemab will get Alzheimer’s nod, however how profitable it is going to be is unsure

agrobacter/iStock through Getty Photos The US FDA on Friday granted accelerated approval to Biogen (NASDAQ:BIIB)…

agrobacter/iStock through Getty Photos

The US FDA on Friday granted accelerated approval to Biogen (NASDAQ:BIIB) and Eisai’s (OTCPK:ESALY) Leqembi (lecanemab), simply the second biologic drugs ever accepted for Alzheimer’s illness.

The remedy is anticipated to turn into out there across the